NASDAQ:AGTC Applied Genetic Technologies (AGTC) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free AGTC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.39▼$0.3950-Day Range$0.37▼$0.4252-Week Range$0.23▼$2.83VolumeN/AAverage Volume943,490 shsMarket Capitalization$26.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Applied Genetic Technologies alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Applied Genetic Technologies Stock (NASDAQ:AGTC)Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report AGTC Stock News HeadlinesApril 22, 2024 | finance.yahoo.comDry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsightFebruary 8, 2024 | finance.yahoo.comBeacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis PigmentosaApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.January 5, 2024 | marketwatch.comMetagenomi Technologies Files for Initial Public OfferingDecember 18, 2023 | msn.comA new mathematical language for biological networksOctober 23, 2023 | investing.comGenetic Technologies (GENE) Earnings Dates & ReportsJune 12, 2023 | lse.co.ukSyncona launches new gene therapy company with GBP96 million fundingJune 1, 2023 | msn.comNew AI tool searches genetic haystacks to find disease-causing variantsApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 17, 2023 | uk.finance.yahoo.comSania Therapeutics launches to advance novel medicines for neural circuit dysfunctionMay 1, 2023 | usnews.comApplied Technology CenterApril 27, 2023 | finance.yahoo.comAAV Vectors in Gene Therapy Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the DomainApril 21, 2023 | msn.comWorld-first technology from biomodal enables reading of genetic and epigenetic information using existing sequencersApril 1, 2023 | nbcnews.comElephant in the dining room: Startup creates mammoth meatballMarch 22, 2023 | bbc.co.ukGenetic control of metabolismMarch 16, 2023 | bbc.co.ukGenetic testing and cystic fibrosisJanuary 31, 2023 | yahoo.comRallybio Announces Appointment of Jonathan I. Lieber as Chief Financial OfficerJanuary 5, 2023 | thestreet.comApplied Genetic Technologies (AGTC) Stock Climbs on $124 Million Biogen DealNovember 28, 2022 | finance.yahoo.com*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*November 22, 2022 | finance.yahoo.com*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*November 15, 2022 | finance.yahoo.comApplied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022November 3, 2022 | finance.yahoo.comApplied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022October 25, 2022 | finance.yahoo.comFlorida investment firm looks to take Cambridge gene therapy startup privateOctober 24, 2022 | lse.co.ukSyncona to acquire retinal therapy firm Applied Genetic TechnologiesOctober 23, 2022 | finance.yahoo.comSyncona to Acquire Applied Genetic Technologies CorporationOctober 18, 2022 | markets.businessinsider.comiNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesisSeptember 30, 2022 | msn.comHC Wainwright & Co. Maintains Buy Rating for Applied Genetic: Here's What You Need To KnowSee More Headlines Receive AGTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/23/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AGTC CUSIPN/A CIK1273636 Webwww.agtc.com Phone(386) 462-2204FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,940,000.00 Net MarginsN/A Pretax Margin-21,537.54% Return on Equity-192.90% Return on Assets-92.54% Debt Debt-to-Equity Ratio0.39 Current Ratio1.40 Quick Ratio1.40 Sales & Book Value Annual Sales$320,000.00 Price / Sales83.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.51Miscellaneous Outstanding Shares67,632,000Free Float64,859,000Market Cap$26.62 million OptionableOptionable Beta1.55 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Susan B. Washer (Age 61)Pres, CEO & Director Comp: $747.84kMr. Jonathan I. Lieber M.B.A. (Age 52)Chief Financial Officer Comp: $533.14kDr. Susan Schneider M.D. (Age 64)Chief Medical Officer Comp: $480.32kDr. Nicholas MuzyczkaCo-FounderDr. Barry J. Byrne M.D.Ph.D., Co-FounderDr. William W. HauswirthCo-Founder & Member of Ophthalmology Scientific Advisory BoardDr. Richard Jude Samulski Ph.D.Co-FounderDr. Terence R. Flotte M.D.Co-FounderMr. Gerald Anthony ReynoldsChief Accounting Officer, Principal Accounting Officer & TreasurerDr. Abraham Scaria Ph.D. (Age 63)Chief Scientific Officer More ExecutivesKey CompetitorsNKGen BiotechNYSE:NKGNAIM ImmunoTechNYSE:AIMPluriNASDAQ:PLURIN8bioNASDAQ:INABMiNK TherapeuticsNASDAQ:INKTView All Competitors AGTC Stock Analysis - Frequently Asked Questions How were Applied Genetic Technologies' earnings last quarter? Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.05. During the same quarter last year, the firm earned ($0.60) EPS. What other stocks do shareholders of Applied Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA). This page (NASDAQ:AGTC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Genetic Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
